Literature DB >> 1663419

Neurobiological mechanisms of opioid tolerance and dependence.

E Collin1, F Cesselin.   

Abstract

The multiplicity of opioid receptors (mu, delta, kappa) and the limited knowledge of their coupling mechanisms explain why cellular and biochemical changes underlying opioid tolerance/dependence remain poorly understood. Following chronic exposure to opioids, both down- and up-regulation of opioid receptors can occur, depending on the receptor type and/or the central region examined. As these changes generally appear after the tolerance is installed, they are very likely not responsible for it. Instead, opioid tolerance seems to be associated with some uncoupling (probably functional rather than physical) of the opioid receptors from G proteins normally associated with them, therefore resulting in a loss of the capacity of these proteins to exchange GDP for GTP. However, considerable variations might exist in the mechanisms underlying tolerance from one opioid receptor type to another. With regard to dependence, an increase in adenylate cyclase activity, and therefore of cyclic AMP levels and certain protein kinase activities, have been claimed to be responsible for this phenomenon in some cell types. As highly selective opioid agonists and antagonists are now available, experiments with such compounds are expected to yield more informative data on the consequences of the chronic stimulation of a given receptor type. This should contribute to a better understanding of the biochemical and cellular events really responsible for the development of morphine tolerance and dependence.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663419     DOI: 10.1097/00002826-199112000-00001

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  14 in total

Review 1.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 2.  Paradoxical signal transduction in neurobiological systems.

Authors:  F C Colpaert; Y Frégnac
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.590

3.  Neurophysiology of Cancer Pain: From the Laboratory to the Clinic.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

4.  Effects of sufentanil and NMDA antagonists on a C-fibre reflex in the rat.

Authors:  F Adam; A C Gairard; M Chauvin; D Le Bars; F Guirimand
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

5.  Variation in tolerance to the antinociceptive, hormonal and thermal effects of morphine after a 5-day pre-treatment of male rats with increasing doses of morphine.

Authors:  P T Männistö; S A Borisenko; P Rauhala; P Tuomainen; R K Tuominen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

6.  Food deprivation increases the mRNA expression of micro-opioid receptors in the ventral medial hypothalamus and arcuate nucleus.

Authors:  Maria J Barnes; Stefany D Primeaux; George A Bray
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-09-03       Impact factor: 3.619

7.  Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine.

Authors:  M M Belcheva; J Barg; R J McHale; S Dawn; M T Ho; E Ignatova; C J Coscia
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

8.  Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.

Authors:  S Salvadori; M Attila; G Balboni; C Bianchi; S D Bryant; O Crescenzi; R Guerrini; D Picone; T Tancredi; P A Temussi
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

Review 9.  Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia.

Authors:  D Eric Brush
Journal:  J Med Toxicol       Date:  2012-12

10.  Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders.

Authors:  Cindy L Kidner; Tom G Mayer; Robert J Gatchel
Journal:  J Bone Joint Surg Am       Date:  2009-04       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.